{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:02:41Z","timestamp":1784941361608,"version":"3.55.0"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"CP","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objective Clinical trials indicate that avatrombopag, a thrombopoietin-receptor agonist (TPO-RA), is safe and effective for treating patients with primary immune thrombocytopenia (ITP), but real-world evidence on its broader clinical effectiveness is limited.<\/jats:p>\n                  <jats:p>Methods This European multi-center retrospective chart review included adults with primary ITP treated with avatrombopag in routine clinical practice, who had medical records available for \u2265 12 weeks before and after avatrombopag initiation.<\/jats:p>\n                  <jats:p>Results Data from 76 patients with ITP (51 TPO-RA na\u00efve, 25 prior TPO-RA exposed) showed a median time of 4.2 years (interquartile range: 0.7\u201310.3) from ITP diagnosis to avatrombopag initiation (index date) and a median follow-up of 15.9 months (interquartile range: 7.8\u201322.8). By week 12, 96 and 93% of the cohort achieved platelet counts (PC) of \u226530 \u00d7 109\/L and \u226550 \u00d7 109\/L, respectively; 72% had a complete response (\u2265100 \u00d7 109\/L) by week 12, 80% by week 26, and 87% by week 52 postindex. PC reached \u226530 \u00d7 109\/L, \u226550 \u00d7 109\/L, and \u2265100 \u00d7 109\/L in a median of 8 (95% confidence interval: 7\u201312), 10 (8\u201314), and 19 (12\u201323) days from the index date, respectively. At 1 year, 75% (n total = 34) and 47% (n total = 21) maintained PC of \u226550 \u00d7 109\/L and \u2265100 \u00d7 109\/L, respectively. Avatrombopag was permanently discontinued by 19 patients (25%), including 7 (37%) due to being candidates for sustained remission off-treatment. Thromboembolic rates were 4.9 (95% confidence interval: 1.3\u201312.5) per 100 patient-years during follow-up. The incidence rate (95% confidence interval) of ITP-related outpatient visits and inpatient admissions was 8.9 (8.2\u20139.5) and 0.1 (0.1\u20130.2) per person-year.<\/jats:p>\n                  <jats:p>Conclusion This study supports clinical trials\u2019 findings and other postmarketing evidence demonstrating the effectiveness of avatrombopag.<\/jats:p>","DOI":"10.1055\/a-2886-7426","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:46:52Z","timestamp":1784940412000},"source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag"],"prefix":"10.1055","volume":"10","author":[{"given":"Quentin A.","family":"Hill","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust, England, United Kingdom of Great Britain and Northern Ireland","place":["Leeds"],"department":["Department of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Trieste, Friuli-Venezia Giulia, Italy","place":["Trieste"]},{"name":"Azienda Sanitaria Universitaria Giuliano Isontina, Friuli-Venezia Giulia, Italy","place":["Trieste"],"department":["Hematology Unit (SC\/UCO)"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Del Carmen Fernandez","family":"S\u00e1nchez de Mora","sequence":"additional","affiliation":[{"name":"Hospital Universitario Reina Sof\u00eda, Spain","place":["C\u00f3rdoba"],"department":["Department of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Cervinek","sequence":"additional","affiliation":[{"name":"University Hospital Brno, South Moravian Region, Czech Republic","place":["Brno"],"department":["Department of Internal Medicine, Hematology and Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Janssens","sequence":"additional","affiliation":[{"name":"UZ Leuven, Flanders, Belgium","place":["Leuven"],"department":["Department of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-9715","authenticated-orcid":false,"given":"Fatemeh Saberi","family":"Hosnijeh","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Evidence & Access, OPEN Health, Netherlands","place":["Rotterdam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Le Treust","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Evidence & Access, OPEN Health, England, United Kingdom of Great Britain and Northern Ireland","place":["London"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Glen","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Evidence & Access, OPEN Health, England, United Kingdom of Great Britain and Northern Ireland","place":["London"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Putnik","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB Publ, Stockholm County, Sweden","place":["Stockholm"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Rich","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB Publ, Stockholm County, Sweden","place":["Stockholm"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[{"name":"Hemophilia Center, University Hospital Frankfurt, HE, Germany","place":["Frankfurt"],"department":["Department of Hemostaseology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"16","key":"ref1","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s40265-021-01613-y","article-title":"Avatrombopag: a review in thrombocytopenia","volume":"81","author":"A Markham","year":"2021","journal-title":"Drugs"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"F Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"D Provan","year":"2010","journal-title":"Blood"},{"issue":"22","key":"ref4","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"D Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"19","key":"ref5","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"N T Connell","year":"2019","journal-title":"Blood"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2024024250","article-title":"Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice","volume":"144","author":"T J Gonz\u00e1lez-L\u00f3pez","year":"2024","journal-title":"Blood"},{"key":"ref7","first-page":"22","article-title":"Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases","volume":"78","author":"C Schiavotto","year":"1993","journal-title":"Haematologica"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1182\/blood.V64.6.1179.1179","article-title":"Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the Cooperative Latin American group on Hemostasis and Thrombosis","volume":"64","author":"J Pizzuto","year":"1984","journal-title":"Blood"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Y Wei","year":"2016","journal-title":"Blood"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"J Gilreath","year":"2021","journal-title":"Drugs"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"W Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"102158","DOI":"10.1016\/j.rpth.2023.102158","article-title":"Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China","volume":"7","author":"H Mei","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"2195016","DOI":"10.1080\/09537104.2023.2195016","article-title":"Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia","volume":"34","author":"S Jain","year":"2023","journal-title":"Platelets"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study","volume":"197","author":"H Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/10543400903105463","article-title":"Statistical methods to analyze adverse events data of randomized clinical trials","volume":"19","author":"O Siddiqui","year":"2009","journal-title":"J Biopharm Stat"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a115507","article-title":"A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)","volume":"131","author":"K Ulm","year":"1990","journal-title":"Am J Epidemiol"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjh.19975","article-title":"Avatrombopag in adults with immune thrombocytopenia: a multicentre real-life observational study in Madrid, Spain (AVAMAD study)","volume":"206","author":"C Pascual-Izquierdo","year":"2025","journal-title":"Br J Haematol"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/bjh.19800","article-title":"Real-world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag\/hetrombopag","volume":"205","author":"H Tian","year":"2024","journal-title":"Br J Haematol"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.27080","article-title":"Avatrombopag for adults with early versus chronic immune thrombocytopenia","volume":"99","author":"Z M Virk","year":"2024","journal-title":"Am J Hematol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/blood-2023-182848","article-title":"Real-world use, effectiveness and safety of romiplostim, eltrombopag and avatrombopag in immune thrombocytopenia: data from the Norwegian ITP registry","volume":"142","author":"R Tomasello","year":"2023","journal-title":"Blood"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","article-title":"Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension","volume":"33","author":"H Al-Samkari","year":"2022","journal-title":"Platelets"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1182\/blood-2023-180738","article-title":"Clinical and economic burden of illness in patients with persistent or chronic primary immune thrombocytopenia treated with TPO-RAs and rituximab","volume":"142","author":"D J Kuter","year":"2023","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000547576","article-title":"Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: a Canadian retrospective cohort study","volume":"220","author":"J Podstawka","year":"2022","journal-title":"Thromb Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000547576","article-title":"Real-world insight into avatrombopag\u2019s effectiveness and safety in adults with primary immune thrombocytopenia: a retrospective analysis from Central and Eastern Europe","author":"B Skopec","year":"2025","journal-title":"Acta Haematol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1182\/blood-2025-6251","article-title":"Real-world treatment patterns and clinical outcomes of therapies in primary immune thrombocytopenia","volume":"146","author":"S Panch","year":"2025","journal-title":"Blood"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/jha2.684","article-title":"Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States","volume":"4","author":"A Cuker","year":"2023","journal-title":"eJHaem"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjh.16775","article-title":"Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic","volume":"189","author":"S Pavord","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/bloodadvances.2024015635","article-title":"Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA","volume":"9","author":"M D Tarantino","year":"2025","journal-title":"Blood Adv"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/ajh.27498","article-title":"Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH). Avatrombopag in immune thrombocytopenia: a real-world study of the Spanish ITP Group (GEPTI)","volume":"99","author":"C Pascual-Izquierdo","year":"2024","journal-title":"Am J Hematol"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12185-015-1837-6","article-title":"Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim","volume":"102","author":"D B Cines","year":"2015","journal-title":"Int J Hematol"},{"issue":"05","key":"ref36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ejh.12181","article-title":"Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials","volume":"91","author":"F Rodeghiero","year":"2013","journal-title":"Eur J Haematol"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.15803","article-title":"Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies","volume":"185","author":"D J Kuter","year":"2019","journal-title":"Br J Haematol"},{"issue":"22","key":"ref38","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.V114.22.2423.2423","article-title":"Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura","volume":"114","author":"J B Bussel","year":"2009","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"100774","DOI":"10.1016\/j.blre.2020.100774","article-title":"Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients","volume":"47","author":"W EM van Dijk","year":"2021","journal-title":"Blood Rev"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3324\/haematol.2009.018390","article-title":"Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database","volume":"95","author":"A Sarpatwari","year":"2010","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.thromres.2019.04.016","article-title":"Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia \u2013 results from two nationwide cohorts","volume":"178","author":"C Ekstrand","year":"2019","journal-title":"Thromb Res"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/jth.12636","article-title":"Gruppo Italiano Malattie EMatologiche dell\u2019Adulto (GIMEMA) Anemia and Thrombocytopenias Working Party. GIMEMA Study ITP0311. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors","volume":"12","author":"M Ruggeri","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2141.2010.08418.x","article-title":"Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study","volume":"152","author":"M T Severinsen","year":"2011","journal-title":"Br J Haematol"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2886-7426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:46:57Z","timestamp":1784940417000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2886-7426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":38,"journal-issue":{"issue":"CP","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026]]}},"alternative-id":["a28867426"],"URL":"https:\/\/doi.org\/10.1055\/a-2886-7426","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}